Open AccessThe Hemagglutinin A Stem Antibody MEDI8852 Prevents and Controls Disease and Limits Transmission of Pandemic Influenza Viruses
Author(s) -
Catharine I. Paules,
Seema S. Lakdawala,
Josephine M. McAuliffe,
Myeisha Paskel,
Leatrice Vogel,
Nicole L. Kallewaard,
Qing Zhu,
Kanta Subbarao
Publication year - 2017
Publication title -
the journal of infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.69
H-Index - 252
eISSN - 1537-6613
pISSN - 0022-1899
DOI - 10.1093/infdis/jix292
Subject(s) - oseltamivir , virology , hemagglutinin (influenza) , influenza a virus subtype h5n1 , titer , transmission (telecommunications) , viral shedding , vaccination , antibody titer , biology , virus , antibody , nasal administration , medicine , microbiology and biotechnology , immunology , covid-19 , disease , infectious disease (medical specialty) , electrical engineering , engineering
MEDI8852 is a novel monoclonal antibody (mAb) that neutralizes both group I and group II influenza A viruses (IAVs) in vitro. We evaluated whether MEDI8852 was effective for prophylaxis and therapy against representative group I (H5N1) and group II (H7N9) pandemic IAVs in mice and ferrets and could be used to block transmission of influenza H1N1pdm09 in ferrets, compared to an irrelevant control mAb R347 and oseltamivir.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom